MARKET

VBLT

VBLT

VASCULAR
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.037
+0.007
+0.35%
Opening 09:30 05/06 EDT
OPEN
2.040
PREV CLOSE
2.030
HIGH
2.040
LOW
2.030
VOLUME
12.65K
TURNOVER
--
52 WEEK HIGH
3.170
52 WEEK LOW
1.012
MARKET CAP
108.66M
P/E (TTM)
-3.6720
1D
5D
1M
3M
1Y
5Y
VBL Therapeutics to Report First Quarter Financial Results on May 11
TEL AVIV, Israel, May 04, 2021 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) will release its first quarter financial results for the period ended March 31, 2021 on Tuesday, May 11, 2021 before market open. Professor Dror Harats, M.D, Chief Executive...
GlobeNewswire · 2d ago
Thyroid Cancer Drugs Market Develop Rapidly by Top Players: Biovista, Vascular Biogenics, Azaya Therapeutics, Bionomics, Bayer, Eisai, Bio-Path Holdings, Takeda Pharmaceutical Company
May 02, 2021 (Market Insight Reports) -- In the recent past, increasing number of thyroid cancers were diagnosed at an early stage of the treatment as...
Market Insight Reports · 3d ago
These 2 Penny Stocks Could Rally Over 100%, Says Oppenheimer
Speaking of economic opportunity, and the general benefits of wide-ranging growth, President John Kennedy once said, “A rising tide lifts all boats.” As the COVID cris...
TipRanks.com · 04/28 14:39
Vascular Biogenics Ltd. Closes Public Offering of Ordinary Shares and Pre-Funded Warrants
TEL AVIV, Israel, Apr 14, 2021 (GLOBE NEWSWIRE via COMTEX) -- TEL AVIV, Israel, April 14, 2021 (GLOBE NEWSWIRE) -- Vascular Biogenics Ltd. ("VBL...
GlobeNewswire · 04/14 10:00
Vascular Biogenics prices $25M stock offering
Vascular Biogenics (VBLT) prices public offering of 5.15M shares, to certain investors in lieu thereof pre-funded warrants to purchase 8.05M shares, at $1.90 per share and $1.89 per pre-funded warrant.Underwriters' overallotment
Seekingalpha · 04/09 13:06
Vascular Biogenics Prices Public Offering Of 5.15M Ordinary Shares At $1.90/Share
Vascular Biogenics Ltd. Prices Public Offering of Ordinary Shares and Pre-Funded Warrants TEL AVIV, Israel, April 09, 2021 (GLOBE NEWSWIRE) -- Vascular Biogenics Ltd. ("VBL Therapeutics" or the
Benzinga · 04/09 12:59
Vascular Biogenics Ltd. Prices Public Offering of Ordinary Shares and Pre-Funded Warrants
TEL AVIV, Israel, Apr 09, 2021 (GLOBE NEWSWIRE via COMTEX) -- TEL AVIV, Israel, April 09, 2021 (GLOBE NEWSWIRE) -- Vascular Biogenics Ltd. ("VBL...
GlobeNewswire · 04/09 12:59
The Daily Biotech Pulse: Negative Regulatory Tidings For Provention Bio, Celcuity Soars On In-licensing Deal, 2 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 8)
Benzinga · 04/09 11:26
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of VBLT. Analyze the recent business situations of VASCULAR through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average VBLT stock price target is 5.00 with a high estimate of 6.00 and a low estimate of 4.000.
EPS
Institutional Holdings
Institutions: 37
Institutional Holdings: 2.56M
% Owned: 4.80%
Shares Outstanding: 53.34M
TypeInstitutionsShares
Increased
1
7.69K
New
8
372.03K
Decreased
4
155.23K
Sold Out
2
109.67K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-1.53%
Pharmaceuticals & Medical Research
-0.65%
Key Executives
Non-Executive Chairman/Independent Director
Bennett Shapiro
Chief Executive Officer/Director
Dror Harats
Chief Financial Officer/Secretary
Amos Ron
Vice President - Operations
Eyal Breitbart
Vice President
Erez Feige
Vice President
Tami Rachmilewitz
Vice President
Naamit Sher
General Counsel
Ayelet Horn
Non-Executive Independent Director
Ruth Alon
Non-Executive Independent Director
Ruth Arnon
Non-Executive Independent Director
Shmuel Ben Zvi
Non-Executive Independent Director
Ron Cohen
Non-Executive Independent Director
David Hastings
Non-Executive Independent Director
Susan Kelley
No Data
  • All
  • Financials
  • Insiders
More
About VBLT
Vascular Biogenics Ltd. is Israel- based late-stage clinical biopharmaceutical company, focused on the discovery, development and commercialization of treatments for cancer. VBL’s clinical pipeline is based on two distinct platform technologies that leverage the body’s natural physiologic and genetic regulatory elements. The Company has developed two programs based on these platforms an oncology program and an anti-inflammatory program. The Company’s lead oncology product VB-111, is a targeted anti-cancer gene-therapy agent that is positioned to potentially treat a wide range of solid tumors. VBL has also developed platform of investigational orally-available small molecules, designated Lecinoxoids, for the treatment of chronic immune-related indications.

Webull offers kinds of Vascular Biogenics Ltd stock information, including NASDAQ:VBLT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VBLT stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading VBLT stock methods without spending real money on the virtual paper trading platform.